Europe Pemphigus Vulgaris Market - Industry Trends and Forecast to 2030

TABLE OF CONTENTS

1 INTRODUCTION 18

• 1.1 OBJECTIVES OF THE STUDY 18
• 1.2 MARKET DEFINITION 18
• 1.3 OVERVIEW 18
• 1.4 CURRENCY AND PRICING 20
• 1.5 LIMITATIONS 20
• 1.6 MARKETS COVERED 20

2 MARKET SEGMENTATION 23

• 2.1 MARKETS COVERED 23
• 2.2 GEOGRAPHICAL SCOPE 24
• 2.3 YEARS CONSIDERED FOR THE STUDY 25
• 2.4 DBMR TRIPOD DATA VALIDATION MODEL 26
• 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 29
• 2.6 MULTIVARIATE MODELLING 30
• 2.7 MARKET APPLICATION COVERAGE GRID 31
• 2.8 PRODUCT LIFELINE CURVE 32
• 2.9 DBMR MARKET POSITION GRID 33
• 2.10 VENDOR SHARE ANALYSIS 34
• 2.11 SECONDARY SOURCES 35
• 2.12 ASSUMPTIONS 35

3 EXECUTIVE SUMMARY 36

4 PREMIUM INSIGHTS 38

• 4.1 PESTEL ANALYSIS 39
• 4.2 PORTER FIVE FORCES 40
• 4.3 PATENT ANALYSIS 41
• 4.4 PATIENT FLOW DIAGRAM 42
• 4.5 KEY PRICING STRATEGIES 43
• 4.6 FUTURE THERAPIES 44
• 4.7 KEY PATIENT ENROLLMENT STRATEGIES 45

5 PIPELINE ANALYSIS 46

6 EPIDEMIOLOGY 47

7 INDUSTRY INSIGHTS 48

8 EUROPE PEMPHIGUS VULGARIS MARKET: REGULATIONS 49

9 MARKET OVERVIEW 52

• 9.1 DRIVERS 54
  • 9.1.1 EMERGING TREATMENT OPTIONS FOR PEMPHIGUS VULGARIS 54
  • 9.1.2 GROWING SUPPORT OF NGOS FOR THE AFFECTED PATIENTS 54
  • 9.1.3 AWARENESS REGARDING THE DISEASE 55
• 9.2 RESTRAINTS 55
  • 9.2.1 STRICT REGULATORY GUIDELINES 55
  • 9.2.2 HIGH TREATMENT COSTS 55
• 9.3 OPPORTUNITIES 56
  • 9.3.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE 56
  • 9.3.2 INCREASING HEALTHCARE FACILITIES 56
  • 9.3.3 DIGITAL HEALTH TECHNOLOGIES FOR TREATMENT MANAGEMENT 57
• 9.4 CHALLENGES 57
  • 9.4.1 ADVERSE EFFECTS ASSOCIATED WITH MEDICATIONS 57
  • 9.4.2 REIMBURSEMENT AND COVERAGE POLICIES 58

10 EUROPE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT 59

• 10.1 OVERVIEW 60
• 10.2 TREATMENT 63
  • 10.2.1 MEDICATIONS, BY TYPE 63
    • 10.2.1.1 CORTICOSTEROIDS 64
    • 10.2.1.2 STEROID- SPARING IMMUNOSUPPRESSANT DRUGS 64
      • 10.2.1.2.1 AZATHIOPRINE 65
      • 10.2.1.2.2 MYCOPHENALATE MOFETIL 65
      • 10.2.1.2.3 METHOTREXATE 65
      • 10.2.1.2.4 CYCLOPHOSPHAMIDE 65
      • 10.2.1.2.5 MIZORIBINE 65
      • 10.2.1.2.6 OTHERS 65
    • 10.2.1.3 ANTI- INFLAMMATORY AGENTS 65
      • 10.2.1.3.1 DIAMINODYPHENYL SULFONE 66
      • 10.2.1.3.2 TETRACYCLINE 66
      • 10.2.1.3.3 OTHERS 66
    • 10.2.1.4 BIOLOGICS 66
    • 10.2.1.5 INTRAVENOUS IMMUNOGLOBULIN 66
    • 10.2.1.6 ANTIBIOTICS 66
    • 10.2.1.7 ANTIFUNGALS 66
    • 10.2.1.8 ANTIVIRALS 66
    • 10.2.1.9 OTHER MEDICATIONS 66
  • 10.2.2 MEDICATIONS, BY ROUTE OF ADMINISTRATION 66
    • 10.2.2.1 ORAL 67
    • 10.2.2.2 TOPICAL 67
    • 10.2.2.3 PARENTERAL 67
    • 10.2.2.4 OTHERS 67
  • 10.2.3 MEDICATIONS, BY DRUG TYPE 67
    • 10.2.3.1 GENERIC 68
    • 10.2.3.2 BRANDED 68
• 10.3 DIAGNOSIS 68
  • 10.3.1 SKIN BIOPSY 69
  • 10.3.2 BLOOD TEST 69
  • 10.3.3 ENDOSCOPY 69

11 EUROPE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE 70

• 11.1 OVERVIEW 71
• 11.2 ADULTS 74
• 11.3 GERIATRIC 75
• 11.4 PEDIATRIC 76

12 EUROPE PEMPHIGUS VULGARIS MARKET, BY END USER 77

• 12.1 OVERVIEW 78
• 12.2 HOSPITALS 81
• 12.3 SPECIALTY CLINICS 81
• 12.4 RESEARCH INSTITUTES 82
• 12.5 OTHERS 83

13 EUROPE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL 84

• 13.1 OVERVIEW 85
• 13.2 HOSPITALS PHARMACY 88
• 13.3 RETAIL PHARMACY 88
• 13.4 ONLINE PHARMACY 89

14 EUROPE PEMPHIGUS VULGARIS MARKET, BY REGION 90

• 14.1 EUROPE 91
  • 14.1.1 GERMANY 100
  • 14.1.2 U.K. 104
  • 14.1.3 FRANCE 108
  • 14.1.4 ITALY 112
  • 14.1.5 SPAIN 116
  • 14.1.6 SWITZERLAND 120
  • 14.1.7 TURKEY 124
  • 14.1.8 RUSSIA 128
  • 14.1.9 BELGIUM 132
  • 14.1.10 NETHERLANDS 136
  • 14.1.11 REST OF EUROPE 139

15 EUROPE PEMPHIGUS VULGARIS MARKET, COMPANY LANDSCAPE 140

• 15.1 COMPANY SHARE ANALYSIS: EUROPE 140

16 SWOT ANALYSIS 141

17 COMPANY PROFILE 142

• 17.1 ABBVIE INC. 142
  • 17.1.1 COMPANY SNAPSHOT 142
  • 17.1.2 REVENUE ANALYSIS 142
  • 17.1.3 COMPANY SHARE ANALYSIS 143
  • 17.1.4 PRODUCT PORTFOLIO 143
  • 17.1.5 RECENT DEVELOPMENTS 144
• 17.2 MERCK & CO., INC., 145
  • 17.2.1 COMPANY SNAPSHOT 145
  • 17.2.2 REVENUE ANALYSIS 145
  • 17.2.3 COMPANY SHARE ANALYSIS 146
  • 17.2.4 PRODUCT PORTFOLIO 146
  • 17.2.5 RECENT DEVELOPMENT 146
• 17.3 SANOFI 147
  • 17.3.1 COMPANY SNAPSHOT 147
  • 17.3.2 REVENUE ANALYSIS 147
  • 17.3.3 COMPANY SHARE ANALYSIS 148
  • 17.3.4 PRODUCT PORTFOLIO 148
  • 17.3.5 RECENT DEVELOPMENT 148
• 17.4 REGENERON PHARMACEUTICALS INC. 149
  • 17.4.1 COMPANY SNAPSHOT 149
  • 17.4.2 REVENUE ANALYSIS 149
  • 17.4.3 COMPANY SHARE ANALYSIS 150
  • 17.4.4 PRODUCT PORTFOLIO 150
  • 17.4.5 RECENT DEVELOPMENT 150
• 17.5 NOVARTIS AG 151
  • 17.5.1 COMPANY SNAPSHOT 151
  • 17.5.2 REVENUE ANALYSIS 151
  • 17.5.3 COMPANY SHARE ANALYSIS 152
  • 17.5.4 PRODUCT PORTFOLIO 152
  • 17.5.5 RECENT DEVELOPMENT 152
• 17.6 AMGEN INC. 153
  • 17.6.1 COMPANY SNAPSHOT 153
  • 17.6.2 REVENUE ANALYSIS 153
  • 17.6.3 PRODUCT PORTFOLIO 154
  • 17.6.4 RECENT DEVELOPMENTS 154
• 17.7 ASTRAZENECA 155
  • 17.7.1 COMPANY SNAPSHOT 155
  • 17.7.2 REVENUE ANALYSIS 155
  • 17.7.3 COMPANY SHARE ANALYSIS 156
  • 17.7.4 PRODUCT PORTFOLIO 156
  • 17.7.5 RECENT DEVELOPMENTS 157
• 17.8 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 158
  • 17.8.1 COMPANY SNAPSHOT 158
  • 17.8.2 REVENUE ANALYSIS 158
  • 17.8.3 PRODUCT PORTFOLIO 159
  • 17.8.4 RECENT DEVELOPMENT 159
• 17.9 CELLTRION HEALTHCARE CO., LTD 160
  • 17.9.1 COMPANY SNAPSHOT 160
  • 17.9.2 REVENUE ANALYSIS 160
  • 17.9.3 PRODUCT PORTFOLIO 161
  • 17.9.4 RECENT DEVELOPMENTS 161
• 17.10 F. HOFFMANN- LA ROCHE LTD. 162
  • 17.10.1 COMPANY SNAPSHOT 162
  • 17.10.2 REVENUE ANALYSIS 162
  • 17.10.3 PRODUCT PORTFOLIO 163
  • 17.10.4 RECENT DEVELOPMENT 163
• 17.11 FRESENIUS KABI AG 164
  • 17.11.1 COMPANY SNAPSHOT 164
  • 17.11.2 REVENUE ANALYSIS 164
  • 17.11.3 PRODUCT PORTFOLIO 165
  • 17.11.4 RECENT DEVELOPMENT 165
• 17.12 GSK PLC 166
  • 17.12.1 COMPANY SNAPSHOT 166
  • 17.12.2 REVENUE ANALYSIS 166
  • 17.12.3 PRODUCT PORTFOLIO 167
  • 17.12.4 RECENT DEVELOPMENT 167
• 17.13 JOHNSON & JOHNSON SERVICES, INC. 168
  • 17.13.1 COMPANY SNAPSHOT 168
  • 17.13.2 REVENUE ANALYSIS 168
  • 17.13.3 COMPANY SHARE ANALYSIS 169
  • 17.13.4 PRODUCT PORTFOLIO 169
  • 17.13.5 RECENT DEVELOPMENT 169
• 17.14 LILLY 170
  • 17.14.1 COMPANY SNAPSHOT 170
  • 17.14.2 REVENUE ANALYSIS 170
  • 17.14.3 PRODUCT PORTFOLIO 171
  • 17.14.4 RECENT DEVELOPMENT 171
• 17.15 PFIZER INC. 172
  • 17.15.1 COMPANY SNAPSHOT 172
  • 17.15.2 REVENUE ANALYSIS 172
  • 17.15.3 PRODUCT PORTFOLIO 173
  • 17.15.4 RECENT DEVELOPMENT 173
• 17.16 RAKSHIT DRUGS PVT. LTD 174
  • 17.16.1 COMPANY SNAPSHOT 174
  • 17.16.2 PRODUCT PORTFOLIO 174
  • 17.16.3 RECENT DEVELOPMENT 174
• 17.17 TEVA PHARMACEUTICAL INDUSTRIES LTD 175
  • 17.17.1 COMPANY SNAPSHOT 175
  • 17.17.2 REVENUE ANALYSIS 175
  • 17.17.3 PRODUCT PORTFOLIO 176
  • 17.17.4 RECENT DEVELOPMENT 176
• 17.18 ZYDUS GROUP 177
  • 17.18.1 COMPANY SNAPSHOT 177
  • 17.18.2 REVENUE ANALYSIS 177
  • 17.18.3 PRODUCT PORTFOLIO 178
  • 17.18.4 RECENT DEVELOPMENT 178

18 QUESTIONNAIRE 179

19 RELATED REPORTS 181

LIST OF TABLES

• TABLE 1 EUROPE PEMPHIGUS VULGARIS MARKET, PATENT ANALYSIS 41
• TABLE 2 EUROPE PEMPHIGUS VULGARIS MARKET, PIPELINE ANALYSIS 46
• TABLE 3 EUROPE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 62
• TABLE 4 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 63
• TABLE 5 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 64
• TABLE 6 EUROPE STEROID- SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 64
• TABLE 7 EUROPE ANTI- INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 65
• TABLE 8 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 67
• TABLE 9 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 67
• TABLE 10 EUROPE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 68
• TABLE 11 EUROPE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 69
• TABLE 12 EUROPE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 73
• TABLE 13 EUROPE ADULTS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 74
• TABLE 14 EUROPE GERIATRIC IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 75
• TABLE 15 EUROPE PEDIATRIC IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 76
• TABLE 16 EUROPE PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 80
• TABLE 17 EUROPE HOSPITALS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 81
• TABLE 18 EUROPE SPECIALTY CLINICS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
• TABLE 19 EUROPE RESEARCH INSTITUTES IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
• TABLE 20 EUROPE OTHERS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 83
• TABLE 21 EUROPE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 87
• TABLE 22 EUROPE HOSPITALS PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 88
• TABLE 23 EUROPE RETAIL PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 89
• TABLE 24 EUROPE ONLINE PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 89
• TABLE 25 EUROPE PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 95
• TABLE 26 EUROPE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 95
• TABLE 27 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 96
• TABLE 28 EUROPE STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 96
• TABLE 29 EUROPE ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 97
• TABLE 30 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 97
• TABLE 31 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 97
• TABLE 32 EUROPE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 98
• TABLE 33 EUROPE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 98
• TABLE 34 EUROPE PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 98
• TABLE 35 EUROPE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 99
• TABLE 36 GERMANY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 100
• TABLE 37 GERMANY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 100
• TABLE 38 GERMANY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 101
• TABLE 39 GERMANY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 101
• TABLE 40 GERMANY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 101
• TABLE 41 GERMANY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 102
• TABLE 42 GERMANY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 102
• TABLE 43 GERMANY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 102
• TABLE 44 GERMANY PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 103
• TABLE 45 GERMANY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 103
• TABLE 46 U.K. PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 104
• TABLE 47 U.K. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 104
• TABLE 48 U.K. STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 105
• TABLE 49 U.K. ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 105
• TABLE 50 U.K. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 105
• TABLE 51 U.K. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 106
• TABLE 52 U.K. DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 106
• TABLE 53 U.K. PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 106
• TABLE 54 U.K. PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 106
• TABLE 55 U.K. PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 107
• TABLE 56 FRANCE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 108
• TABLE 57 FRANCE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 108
• TABLE 58 FRANCE STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 109
• TABLE 59 FRANCE ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 109
• TABLE 60 FRANCE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 109
• TABLE 61 FRANCE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 110
• TABLE 62 FRANCE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 110
• TABLE 63 FRANCE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 110
• TABLE 64 FRANCE PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 110
• TABLE 65 FRANCE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 111
• TABLE 66 ITALY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 112
• TABLE 67 ITALY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 112
• TABLE 68 ITALY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 113
• TABLE 69 ITALY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 113
• TABLE 70 ITALY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 113
• TABLE 71 ITALY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 114
• TABLE 72 ITALY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 114
• TABLE 73 ITALY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 114
• TABLE 74 ITALY PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 114
• TABLE 75 ITALY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 115
• TABLE 76 SPAIN PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 116
• TABLE 77 SPAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 116
• TABLE 78 SPAIN STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 117
• TABLE 79 SPAIN ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 117
• TABLE 80 SPAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 117
• TABLE 81 SPAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 118
• TABLE 82 SPAIN DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 118
• TABLE 83 SPAIN PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 118
• TABLE 84 SPAIN PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 118
• TABLE 85 SPAIN PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 119
• TABLE 86 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 120
• TABLE 87 SWITZERLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 120
• TABLE 88 SWITZERLAND STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 121
• TABLE 89 SWITZERLAND ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 121
• TABLE 90 SWITZERLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 121
• TABLE 91 SWITZERLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 121
• TABLE 92 SWITZERLAND DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 122
• TABLE 93 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 122
• TABLE 94 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 122
• TABLE 95 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 123
• TABLE 96 TURKEY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 124
• TABLE 97 TURKEY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 124
• TABLE 98 TURKEY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 125
• TABLE 99 TURKEY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 125
• TABLE 100 TURKEY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 125
• TABLE 101 TURKEY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 126
• TABLE 102 TURKEY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 126
• TABLE 103 TURKEY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 126
• TABLE 104 TURKEY PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 126
• TABLE 105 TURKEY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 127
• TABLE 106 RUSSIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 128
• TABLE 107 RUSSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 128
• TABLE 108 RUSSIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 129
• TABLE 109 RUSSIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 129
• TABLE 110 RUSSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 129
• TABLE 111 RUSSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 130
• TABLE 112 RUSSIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 130
• TABLE 113 RUSSIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 130
• TABLE 114 RUSSIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 130
• TABLE 115 RUSSIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 131
• TABLE 116 BELGIUM PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 132
• TABLE 117 BELGIUM TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 132
• TABLE 118 BELGIUM STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 133
• TABLE 119 BELGIUM ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 133
• TABLE 120 BELGIUM TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 133
• TABLE 121 BELGIUM TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 134
• TABLE 122 BELGIUM DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 134
• TABLE 123 BELGIUM PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 134
• TABLE 124 BELGIUM PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 134
• TABLE 125 BELGIUM PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 135
• TABLE 126 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 136
• TABLE 127 NETHERLANDS TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 136
• TABLE 128 NETHERLANDS STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 137
• TABLE 129 NETHERLANDS ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 137
• TABLE 130 NETHERLANDS TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 137
• TABLE 131 NETHERLANDS TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 137
• TABLE 132 NETHERLANDS DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 138
• TABLE 133 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 138
• TABLE 134 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 138
• TABLE 135 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 138
• TABLE 136 REST OF EUROPE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 139

LIST OF FIGURES

• FIGURE 1 EUROPE PEMPHIGUS VULGARIS MARKET: SEGMENTATION 23
• FIGURE 2 EUROPE PEMPHIGUS VULGARIS MARKET: DATA TRIANGULATION 26
• FIGURE 3 EUROPE PEMPHIGUS VULGARIS MARKET: DROC ANALYSIS 27
• FIGURE 4 EUROPE PEMPHIGUS VULGARIS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 28
• FIGURE 5 EUROPE PEMPHIGUS VULGARIS MARKET: COMPANY RESEARCH ANALYSIS 28
• FIGURE 6 EUROPE PEMPHIGUS VULGARIS MARKET: INTERVIEW DEMOGRAPHICS 29
• FIGURE 7 EUROPE PEMPHIGUS VULGARIS MARKET: MARKET APPLICATION COVERAGE GRID 31
• FIGURE 8 EUROPE PEMPHIGUS VULGARIS MARKET: DBMR MARKET POSITION GRID 33
• FIGURE 9 EUROPE PEMPHIGUS VULGARIS MARKET: VENDOR SHARE ANALYSIS 34
• FIGURE 10 EUROPE PEMPHIGUS VULGARIS MARKET: SEGMENTATION 37
• FIGURE 11 THE EMERGING TREATMENT OPTIONS FOR THE PEMPHIGUS VULGARISIS EXPECTED TO DRIVE THE GROWTH OF THE EUROPE PEMPHIGUS VULGARIS MARKET FROM 2023 TO 2030 38
• FIGURE 12 THE DIAGNOSIS AND TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE PEMPHIGUS VULGARIS MARKET IN 2023 AND 2030 38
• FIGURE 13 PATIENT FLOW DESCRIPTION OF PEMPHIGUS VULGARIS:- 42
• FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE PEMPHIGUS VULGARIS MARKET 53
• FIGURE 15 EUROPE PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, 2022 60
• FIGURE 16 EUROPE PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, 2023-2030 (USD MILLION) 61
• FIGURE 17 EUROPE PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, CAGR (2023-2030) 61
• FIGURE 18 EUROPE PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, LIFELINE CURVE 62
• FIGURE 19 EUROPE PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, 2022 71
• FIGURE 20 EUROPE PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, 2023-2030 (USD MILLION) 72
• FIGURE 21 EUROPE PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, CAGR (2023-2030) 72
• FIGURE 22 EUROPE PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, LIFELINE CURVE 73
• FIGURE 23 EUROPE PEMPHIGUS VULGARIS MARKET: BY END USER, 2022 78
• FIGURE 24 EUROPE PEMPHIGUS VULGARIS MARKET: BY END USER, 2023-2030 (USD MILLION) 79
• FIGURE 25 EUROPE PEMPHIGUS VULGARIS MARKET: BY END USER, CAGR (2023-2030) 79
• FIGURE 26 EUROPE PEMPHIGUS VULGARIS MARKET: BY END USER, LIFELINE CURVE 80
• FIGURE 27 EUROPE PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, 2022 85
• FIGURE 28 EUROPE PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 86
• FIGURE 29 EUROPE PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 86
• FIGURE 30 EUROPE PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 87
• FIGURE 31 EUROPE PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2022) 92
• FIGURE 32 EUROPE PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022) 93
• FIGURE 33 EUROPE PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2023 & 2030) 93
• FIGURE 34 EUROPE PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022 & 2030) 94
• FIGURE 35 EUROPE PEMPHIGUS VULGARIS MARKET: DIAGNOSIS AND TREATMENT (2023-2030) 94
• FIGURE 36 EUROPE PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2022 (%) 140